TransCode Therapeutics Stock (NASDAQ: RNAZ)

Dernières nouvelles pour TransCode Therapeutics (NASDAQ:RNAZ) Stock

TransCode Therapeutics

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

News

KKR Extends FUJI SOFT Tender Offer Deadline To February 7 Amid Bain Capital's Potential Rival Bid

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index Preliminary For January 51.2 Vs. 50.8 Est.; 51.1 (Revised) Prior

U.K. Manufacturing Purchasing Managers Index Preliminary For January 48.2 Vs. 46.9 Est.; 47.0 (Revised) Prior

U.K. Composite Purchasing Managers' Index Preliminary For January 50.9 Vs. 50.0 Est.; 50.4 Prior

Eurozone Services Purchasing Managers Index Preliminary For January 51.4 Vs. 51.4 Est.; 51.6 (Revised) Prior

HCOB Eurozone Composite Purchasing Managers Index Preliminary For January 50.2 Vs. 49.7 Est.; 49.6 Prior

Eurozone Manufacturing Purchasing Managers Index Preliminary For January 46.1 Vs. 45.6 Est.; 45.1 (Revised) Prior

Piper Sandler analyst Arvind Ramnani maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Overweight and raises the price target from $322 to $368.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Visa, Raises Price Target to $368

Piper Sandler analyst Arvind Ramnani maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Neutral and raises the price target from $88 to $93.

PYPL

Piper Sandler Maintains Neutral on PayPal Holdings, Raises Price Target to $93

Germany Services Purchasing Managers Index Preliminary For January 52.5 Vs. 51.1 Est.; 51.2 (Revised) Prior

Germany Manufacturing Purchasing Managers Index Preliminary For January 44.1 Vs. 42.7 Est.; 42.5 Prior

France Services Purchasing Managers Index Preliminary For January 48.9 Vs. 49.3 Est.; 49.3 (Revised) Prior

Piper Sandler analyst Arvind Ramnani maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $575 to $591.

Piper Sandler Maintains Overweight on Mastercard, Raises Price Target to $591

France Manufacturing Purchasing Managers Index Preliminary For January 45.3 Vs. 42.4 Est.; 41.9 Prior

American EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is recalling over 1.2 million vehicles in China including both imported and domestically produced vehicles.
What Happened:&nbsp;The company is recalling 335,716 vehicles including imported Model S, X vehicles, and domestically manufactured Model 3 and Y vehicles citing concerns about a rearview camera malfunction. The vehicle may not possibly display a reversing image, increasing the risk of a crash, according to a recall notice published on China&#8217;s State Administration for Market Regulation website.
The company is also recalling 871,087 Model 3, Y vehicles citing concerns about the electronic power steering function. The power steering function may fail and pose a safety hazard, the notice said. 
The company will fix both issues via over-the-air software updates. 
Why It Matters: Tesla recalled <a href="https://www.benzinga.com/tech/25/01/42909595/tesla-recalls-over-239000-vehicles-over-rearview-camera-image-display-issues">239,382 vehicles in the U.S.</a> over concerns of loss of rearview camera image earlier this month. The recall population included&nbsp;2024-25 Model 3 and Model S vehicles and 2023-25 Model X and Model Y.
The American EV maker has a <a href="https://www.benzinga.com/tech/25/01/42907586/tesla-model-3-prices-rise-in-china-as-refreshed-model-y-debuts">gigafactory in Shanghai </a>which manufactures Model Y and Model 3 for both sale within the country and export to regions including Europe.
According to Tesla&#8217;s latest quarterly report, the factory in Shanghai has a currently installed annual vehicle capacity of over 950,000 vehicles. The factory produced its 3 millionth vehicle in October and exported its 1 millionth vehicle in September. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43183608/tesla-launches-refreshed-model-y-variant-in-us-canada-after-china">Tesla Launches Refreshed Model Y In US With 25% Price Hike, Full Self-Driving Included</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Recalls Over 1.2 Million Vehicles In China Over Rear View Camera Malfunction, Power Steering Failure Concerns

After U.S. President Donald Trump announced the <a href="https://www.benzinga.com/markets/equities/25/01/43121798/elon-musk-says-project-stargate-doesnt-actually-have-the-money-after-trump-announces-500-billion-ai-investment-led-by-softbank-oracle-and-openai">ambitious $500 billion</a> Stargate project, its initial equity funders SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>), OpenAI, Oracle Corp., and MGX along with its technology partners Nvidia Corp. and Microsoft Corp. have been in focus. We examine which of these U.S.-listed beneficiaries are the least expensive to own by the investors.
What Happened: Oracle, Nvidia, and Microsoft are the three U.S.-listed companies that are directly involved in the Stargate project.
According to the data cumulated from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Microsoft and Oracle are valued less than two times their peers based on the forward price-to-earnings ratio. While Nvidia&#8217;s valuation is just slightly lower than its peers.
Based on the forward P/E:
<ul>
<li>Oracle is 2.72 times less expensive than its industry average.</li>
</ul>
<ul>
<li>Microsoft is 2.41 times cheaper as compared to its peers.</li>
</ul>
<ul>
<li>Nvidia is just 1.08 times less expensive compared to its industry average.</li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>Forward P/E</td>
<td>Industry Average</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>34.364</td>
<td>37.03</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>33.898</td>
<td>81.74</td>
</tr>
<tr>
<td>Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)</td>
<td>30.03</td>
<td>81.74</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a></figcaption></figure>
Thus, Oracle is the least expensive stock to hold among the direct Stargate participants.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/01/43156862/tesla-rivals-rivian-lucid-fall-sharply-after-donald-trump-revokes-bidens-ev-targets-freezes-infra-funding-heres-what-technical-analysis-says">Tesla Rivals Rivian, Lucid Fall Sharply After Donald Trump Revokes Biden&#8217;s EV Targets, Freezes Infra Funding: Here&#8217;s What Technical Analysis Says </a>
Why It Matters: The project, announced Tuesday during a White House briefing with President Trump, marks a collaboration between OpenAI, SoftBank, and Oracle to create a vast artificial intelligence infrastructure across the U.S.
The primary technology partners involved are Arm, Microsoft, Nvidia, Oracle, and OpenAI. The development is already underway in Texas, starting with a 500,000-square-foot data center in Abilene, with additional locations being assessed nationwide as final agreements are being made for more campuses.
The initiative aims to invest $100 billion right away, with plans for nine additional facilities and the possibility of expanding to 20 locations.
Tesla Inc. CEO Elon Musk <a href="https://www.benzinga.com/news/25/01/43173306/elon-musk-says-project-stargate-doesnt-actually-have-the-money-after-trump-announces-500-billion-ai">questioned</a> the project just hours after its announcement, stating that lead investor SoftBank Group has "well under $10B secured."
Musk said in an X post dated Jan. 22 that &#8220;They don&#8217;t actually have the money.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SoftBank has well under $10B secured. I have that on good authority.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1881944244480565497?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: The exchange-traded fund tracking the AI stocks, Invesco AI and Next Gen Software ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGPT#NYSE">IGPT</a>) has risen by 9.72% over the last six months and 19.08% over the last year. While MSFT underperformed the ETF, both Nvidia and Oracle have outperformed IGPT in the same period.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index/ETF</td>
<td>Six Months</td>
<td>One Year</td>
</tr>
<tr>
<td>Nvidia Corporation</td>
<td>28.86%</td>
<td>139.93%</td>
</tr>
<tr>
<td>Oracle Corporation</td>
<td>34.37%</td>
<td>63.13%</td>
</tr>
<tr>
<td>Microsoft Corporation</td>
<td>4.15%</td>
<td>10.97%</td>
</tr>
<tr>
<td>Invesco AI and Next Gen Software ETF</td>
<td>9.72%</td>
<td>19.08%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/43157322/pltr-stock-is-up-166-in-last-6-months-now-dan-ives-sees-room-for-17-more-growth-our-recent-checks-and-growing-confidenceis-key-to-the-bull-thesis">PLTR Stock Is Up 166% In Last 6 Months. Now Dan Ives Sees Room For 17% More Growth: &#8216;Our Recent Checks And Growing Confidence…Is Key To The Bull Thesis&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Sector ETFs

Emerging Markets

Markets

ETFs

General

IGPT

MSFT

NVDA

ORCL

SFTBY

Nvidia, Microsoft, Or Oracle: Which Stock Among These Stargate AI Project Beneficiaries Are The Least Expensive To Own?

<h3>Companies Reporting Before The Bell</h3>
• Bright Scholar Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEDU#NYSE">BEDU</a>) is expected to report earnings for its first quarter. 
• Moog Inc. Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOG#NYSE">MOG</a>) is expected to report quarterly earnings at $1.70 per share on revenue of $873.04 million. 
• Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) is projected to report quarterly earnings at $1.10 per share on revenue of $33.73 billion. 
• South Plains Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPFI#NASDAQ">SPFI</a>) is projected to report quarterly earnings at $0.68 per share on revenue of $49.16 million. 
• First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) is estimated to report quarterly earnings at $39.14 per share on revenue of $2.21 billion. 
• Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) is estimated to report quarterly earnings at $0.90 per share on revenue of $63.09 million. 
• Northwest Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $141.53 million. 
• NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $7.98 billion. 
• HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) is likely to report quarterly earnings at $6.16 per share on revenue of $18.23 billion. 
• Telefonaktiebolaget L M (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $7.01 billion. 
• American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) is expected to report quarterly earnings at $2.98 per share on revenue of $17.14 billion. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BEDU

ERIC

FCNCA

LKFN

NWBI

SPFI

Earnings Scheduled For January 24, 2025

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, while the index moved to the &#8220;Neutral&#8221; zone on Thursday.
U.S. stocks settled higher on Thursday, with the S&amp;P 500 surging to record highs during the session after President Donald Trump called for cheaper oil prices.
Trump addressed the World Economic Forum via videoconference, advocating for expanded oil &amp; gas production and proposing a 15% corporate tax rate for businesses relocating manufacturing to the U.S. He also reiterated plans to impose tariffs on countries with large trade deficits with the U.S., issuing warnings to Europe, Canada, and China.
American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) reported better-than-expected fourth-quarter 2024 results but issued a weak outlook. GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) reported stronger-than-expected earnings for its fourth quarter.
On the economic data front, U.S. initial jobless claims increased by 6,000 from the previous week to 223,000 in the week ending Jan. 18, compared to market estimates of 220,000.
All sectors on the S&amp;P 500 closed on a positive note, with health care, real estate, and industrials stocks recording gains on Thursday.
The Dow Jones closed higher by around 408 points to 44,565.07 on Thursday. The S&amp;P 500 rose 0.53% to 6,118.71, while the Nasdaq Composite climbed 0.22% at 20,053.68 during Thursday's session.
Investors are awaiting earnings results from HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>, )) and American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 47, the index moved to the &#8220;Neutral&#8221; zone on Thursday, versus a prior reading of 42.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Trading Ideas

S&P 500 Surges To Fresh Record Following Trump's Comments: Fear & Greed Index Moves To 'Neutral' Zone

HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/HCA/earnings">opening bell on Friday, Jan. 24, 2025.</a>
Analysts expect the Nashville, Tennessee-based company to report quarterly earnings at $6.14 per share, up from $5.9 per share in the year-ago period. HCA Healthcare projects to report revenue of $18.23 billion for the recent quarter, compared to $17.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 20, 2024, HCA Healthcare named Wendy Warren as Senior Vice President and Chief Ethics and Compliance Officer.
HCA Healthcare shares gained 1.8% to close at $325.36 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/hca/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $430 to $390 on Jan. 6, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Raymond James analyst John Ransom downgraded the stock from Outperform to Market Perform on Nov. 22, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Keybanc analyst Matthew Gillmor maintained an Overweight rating and cut the price target from $475 to $420 on Oct. 28, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating and raised the price target from $390 to $400 on Oct. 28, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Deutsche Bank analyst Pito Chickering maintained a Buy rating and raised the price target from $359 to $375 on June 28, 2024. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying HCA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24024655/image-177-1024x575.png" alt="" class="wp-image-748199" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24024655/image-177-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24024655/image-177-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24024655/image-177-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24024655/image-177.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

HCA Healthcare Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

A dividend for 2024 of SEK 2.85 (2.70) per share will be proposed to the AGM by the Board of Directors.&nbsp;

Dividends

Ericsson Board Will Propose A 2024 Dividend Per Share Of SEK 2.85 (up from SEK 2.70 YoY)

TransCode Therapeutics announces $8M private offering

TransCode Therapeutics ( ($RNAZ) ) has provided an update. TransCode Therapeutics has announced a 1-for-33 reverse stock split aimed at boosting it...

TransCode Therapeutics Announces Reverse Stock Split

TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4

TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. TransCode Therapeutics, Inc. recently executed a private placement agreement with in...

TransCode Therapeutics Raises $8M in Private Placement

19:50 EST Transcode Therapeutics (RNAZ) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...

Transcode Therapeutics Inc trading halted, news pending

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved op...

Transcode announces SRC approved third cohort in TTX-MC138 clinical trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and Tra...

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)

TransCode Therapeutics (RNAZ) announced that it has received notice from the Nasdaq Stock Market that the company has regained compliance with List...

Transcode Therapeutics regains Nasdaq compliance

TransCode Therapeutics regains compliance with Nasdaq

TransCode Therapeutics (RNAZ) announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead ca...

Transcode Therapeutics doses first patient in third cohort of Phase 1trial

RNAZ

VKTX

Biotech

Health Care

Press Releases

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

Financing

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Comments

TransCode Therapeutics

Actualités

Dernières nouvelles pour TransCode Therapeutics (NASDAQ:RNAZ) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL